Cancer remains one of the leading causes of death worldwide. However, rapid advancements in medical technology are transforming screening strategies, enabling earlier detection and significantly improving survival rates. Detecting cancers such as breast, cervical, colorectal, and lung cancers at early stages (stage 0 or I) can result in a 90–100% chance of successful treatment, lower treatment costs, and reduced physical and emotional burden for patients.
Breakthrough Technologies
-
Liquid Biopsy: Detects tumor DNA (ctDNA) circulating in the blood, offering a non-invasive and broad screening option for cancers like lung, colorectal, and liver.
-
AI-powered Imaging: Artificial intelligence helps analyze X-ray, CT, and MRI images to detect subtle lesions often missed by the human eye. AI integration in PACS and imaging devices is improving diagnostic accuracy.
-
Multi-Cancer Early Detection (MCED) Tests: A single blood sample can screen for multiple cancers simultaneously, a technology spearheaded by biotech leaders like GRAIL and Guardant Health.
Effective Screening Strategies
Screening is most effective when personalized to individual risk factors (genetics, lifestyle, and medical history), combined with regular check-ups for high-risk groups (family cancer history, smokers, obesity, HBV/HPV infection), and community awareness programs that emphasize early testing and expand access to screening services.
Delta Medical’s Role
Delta Medical proudly supplies advanced solutions from global brands like Canon Medical, Abbott, and Roche, including molecular diagnostics systems, high-resolution ultrasound and CT, and automated anatomical pathology equipment—helping hospitals implement modern and efficient cancer screening programs.